USPTO serial 87158910
CHOLESTOSOME
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- STEEL, ALYSSA PALADINO
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with CHOLESTOSOME?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
8835 Feusisberg, CH
8835 Feusisberg, CH
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
R. Neil Sudol
R. NEIL SUDOL COSUD INTELLECTUAL PROPERTY SOLUTIONS, P.C.714 COLORADO AVENUEBRIDGEPORT, CT 06605-1601UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of any or all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, and cancers of all types, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), ankylosing spondylitis and vaccines and vaccination to prevent or treat infectious diseases and cancer; pharmaceutical preparations, namely, lipid vesicles encapsulating pharmaceuticals for the treatment of Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of any or all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, and cancers of all types, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), ankylosing spondylitis and vaccines and vaccination to prevent or treat infectious diseases and cancer; pharmaceutical preparations, namely, vesicles made of cholesteryl ester and containing pharmaceuticals for use in the treatment of Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of any or all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, and cancers of all types, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), ankylosing spondylitis, and vaccines and vaccination to prevent or treat infectious diseases and cancer | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 29, 2018 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Oct 29, 2018 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 20, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 16, 2018 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Mar 16, 2018 | EXT2 | SOU EXTENSION 2 FILED | — |
| Mar 16, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 5, 2017 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 1, 2017 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Sep 1, 2017 | EXT1 | SOU EXTENSION 1 FILED | — |
| Sep 1, 2017 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 1, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 28, 2017 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 31, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 31, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 11, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 19, 2016 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 14, 2016 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 14, 2016 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 14, 2016 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 14, 2016 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 10, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 8, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 5, 2016 | NWAP | NEW APPLICATION ENTERED | — |